Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Mikhael

Showing results (41-50 of 104) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2005
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistanceWilfrid Jaksic, Suzanne Trudel, Hong Chang, et al.
Blood Cancer Journal|September 8, 2018
Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG studyJoseph Mikhael, Judith Manola, Amylou C Dueck, et al.
Mayo Clinic Proceedings|December 14, 2005
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantationYoung Trieu, Suzanne Trudel, Gregory R Pond, et al.
Journal of the American Geriatrics Society|December 15, 2018
Geriatric Assessment in Older Adults with Multiple MyelomaTanya M Wildes, Sascha A Tuchman, Heidi D Klepin, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|October 13, 2016
Living with Cancer: an Educational Intervention in Cancer Patients Can Improve Patient-Reported Knowledge DeficitLeslie Padrnos, Robert Bennett, Heidi Kosiorek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myelomaDonna E Reece, Giovanni Piza Rodriguez, Christine Chen, et al.
Blood Cancer Journal|December 18, 2023
Addressing the disparities: the approach to the African American patient with multiple myelomaManisha Bhutani, Brandon J Blue, Craig Cole, et al.
Blood Cancer Journal|December 14, 2017
Systolic dysfunction associated with carfilzomib use in patients with multiple myelomaTania Jain, Hemalatha Narayanasamy, Joseph Mikhael, et al.
Leukemia & Lymphoma|February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparisonKatja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 18, 2024
Effects of Socioeconomic Status and Healthcare Resource Availability on Survival in Older (≥66 years) Non-Hispanic Black Patients Versus Non-Hispanic White Patients With Multiple MyelomaSophia S Li, Robert Schuldt, Faiza Zafar, et al.
Pageof 11

Showing results (41-50 of 104) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2005
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistanceWilfrid Jaksic, Suzanne Trudel, Hong Chang, et al.
Blood Cancer Journal|September 8, 2018
Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG studyJoseph Mikhael, Judith Manola, Amylou C Dueck, et al.
Mayo Clinic Proceedings|December 14, 2005
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantationYoung Trieu, Suzanne Trudel, Gregory R Pond, et al.
Journal of the American Geriatrics Society|December 15, 2018
Geriatric Assessment in Older Adults with Multiple MyelomaTanya M Wildes, Sascha A Tuchman, Heidi D Klepin, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|October 13, 2016
Living with Cancer: an Educational Intervention in Cancer Patients Can Improve Patient-Reported Knowledge DeficitLeslie Padrnos, Robert Bennett, Heidi Kosiorek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myelomaDonna E Reece, Giovanni Piza Rodriguez, Christine Chen, et al.
Blood Cancer Journal|December 18, 2023
Addressing the disparities: the approach to the African American patient with multiple myelomaManisha Bhutani, Brandon J Blue, Craig Cole, et al.
Blood Cancer Journal|December 14, 2017
Systolic dysfunction associated with carfilzomib use in patients with multiple myelomaTania Jain, Hemalatha Narayanasamy, Joseph Mikhael, et al.
Leukemia & Lymphoma|February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparisonKatja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 18, 2024
Effects of Socioeconomic Status and Healthcare Resource Availability on Survival in Older (≥66 years) Non-Hispanic Black Patients Versus Non-Hispanic White Patients With Multiple MyelomaSophia S Li, Robert Schuldt, Faiza Zafar, et al.
Pageof 11